Therapeutic approaches to enhance natural killer cell cytotoxicity against cancer: the force awakens
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Therapeutic approaches to enhance natural killer cell cytotoxicity against cancer: the force awakens
Authors
Keywords
-
Journal
NATURE REVIEWS DRUG DISCOVERY
Volume 14, Issue 7, Pages 487-498
Publisher
Springer Nature
Online
2015-05-22
DOI
10.1038/nrd4506
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Redistribution, Hyperproliferation, Activation of Natural Killer Cells and CD8 T Cells, and Cytokine Production During First-in-Human Clinical Trial of Recombinant Human Interleukin-15 in Patients With Cancer
- (2015) Kevin C. Conlon et al. JOURNAL OF CLINICAL ONCOLOGY
- Expansion and Homing of Adoptively Transferred Human Natural Killer Cells in Immunodeficient Mice Varies with Product Preparation and In Vivo Cytokine Administration: Implications for Clinical Therapy
- (2014) Jeffrey S. Miller et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Clearance of acute myeloid leukemia by haploidentical natural killer cells is improved using IL-2 diphtheria toxin fusion protein
- (2014) V. Bachanova et al. BLOOD
- A phase II trial of pan-KIR2D blockade with IPH2101 in smoldering multiple myeloma
- (2014) N. Korde et al. HAEMATOLOGICA
- Preassociation of IL-15 with IL-15R -IgG1-Fc Enhances Its Activity on Proliferation of NK and CD8+/CD44high T Cells and Its Antitumor Action
- (2014) S. Dubois et al. JOURNAL OF IMMUNOLOGY
- Cutting Edge: The Metalloproteinase ADAM17/TNF- -Converting Enzyme Regulates Proteolytic Shedding of the MHC Class I-Related Chain B Protein
- (2014) P. Boutet et al. JOURNAL OF IMMUNOLOGY
- Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial
- (2014) Caroline Robert et al. LANCET
- Ultra-low Dose Interleukin-2 Promotes Immune-modulating Function of Regulatory T Cells and Natural Killer Cells in Healthy Volunteers
- (2014) Sawa Ito et al. MOLECULAR THERAPY
- IL-12 Directs Further Maturation of Ex Vivo Differentiated NK Cells with Improved Therapeutic Potential
- (2014) Dorit Lehmann et al. PLoS One
- NK cell CD16 surface expression and function is regulated by a disintegrin and metalloprotease-17 (ADAM17)
- (2013) R. Romee et al. BLOOD
- CMV reactivation after allogeneic HCT and relapse risk: evidence for early protection in acute myeloid leukemia
- (2013) M. L. Green et al. BLOOD
- Growth and Activation of Natural Killer Cells Ex Vivo from Children with Neuroblastoma for Adoptive Cell Therapy
- (2013) Y. Liu et al. CLINICAL CANCER RESEARCH
- Targeting Natural Killer Cells to Acute Myeloid Leukemia In Vitro with a CD16 x 33 Bispecific Killer Cell Engager and ADAM17 Inhibition
- (2013) A. Wiernik et al. CLINICAL CANCER RESEARCH
- Doxorubicin sensitizes human tumor cells to NK cell- and T-cell-mediated killing by augmented TRAIL receptor signaling
- (2013) Erik Wennerberg et al. INTERNATIONAL JOURNAL OF CANCER
- Safety, Efficacy, and Biomarkers of Nivolumab With Vaccine in Ipilimumab-Refractory or -Naive Melanoma
- (2013) Jeffrey S. Weber et al. JOURNAL OF CLINICAL ONCOLOGY
- CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma
- (2013) J Chu et al. LEUKEMIA
- Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
- (2013) Omid Hamid et al. NEW ENGLAND JOURNAL OF MEDICINE
- Bringing natural killer cells to the clinic: ex vivo manipulation
- (2013) R. W. Childs et al. Hematology-American Society of Hematology Education Program
- Therapeutic applications: natural killer cells in the clinic
- (2013) J. S. Miller Hematology-American Society of Hematology Education Program
- PD-1 Expression on Peripheral Blood Cells Increases with Stage in Renal Cell Carcinoma Patients and Is Rapidly Reduced after Surgical Tumor Resection
- (2013) A. W. MacFarlane et al. Cancer Immunology Research
- Engineering lymph node homing of ex vivo-expanded human natural killer cells via trogocytosis of the chemokine receptor CCR7
- (2012) S. S. Somanchi et al. BLOOD
- Single-agent lenalidomide in relapsed/refractory mantle cell lymphoma: results from a UK phase II study suggest activity and possible gender differences
- (2012) Heather E. Eve et al. BRITISH JOURNAL OF HAEMATOLOGY
- Large-scale ex vivo expansion and characterization of natural killer cells for clinical applications
- (2012) Natalia Lapteva et al. CYTOTHERAPY
- A clinically adaptable method to enhance the cytotoxicity of natural killer cells against B-cell malignancies
- (2012) Noriko Shimasaki et al. CYTOTHERAPY
- Postallograft lenalidomide induces strong NK cell–mediated antimyeloma activity and risk for T cell–mediated GvHD: Results from a phase I/II dose-finding study
- (2012) Christine Wolschke et al. EXPERIMENTAL HEMATOLOGY
- Highly activated and expanded natural killer cells for multiple myeloma immunotherapy
- (2012) T. K. Garg et al. HAEMATOLOGICA
- Unlicensed NK cells target neuroblastoma following anti-GD2 antibody treatment
- (2012) Nidale Tarek et al. JOURNAL OF CLINICAL INVESTIGATION
- Human Cytomegalovirus (CMV)-Induced Memory-like NKG2C+ NK Cells Are Transplantable and Expand In Vivo in Response to Recipient CMV Antigen
- (2012) B. Foley et al. JOURNAL OF IMMUNOLOGY
- Bispecific and Trispecific Killer Cell Engagers Directly Activate Human NK Cells through CD16 Signaling and Induce Cytotoxicity and Cytokine Production
- (2012) M. K. Gleason et al. MOLECULAR CANCER THERAPEUTICS
- Exploiting a natural conformational switch to engineer an interleukin-2 ‘superkine’
- (2012) Aron M. Levin et al. NATURE
- Anti-CD20 Antibody Therapy for B-Cell Lymphomas
- (2012) David G. Maloney NEW ENGLAND JOURNAL OF MEDICINE
- Membrane-Bound IL-21 Promotes Sustained Ex Vivo Proliferation of Human Natural Killer Cells
- (2012) Cecele J. Denman et al. PLoS One
- Successful transfer of alloreactive haploidentical KIR ligand-mismatched natural killer cells after infusion in elderly high risk acute myeloid leukemia patients
- (2011) A. Curti et al. BLOOD
- Early human cytomegalovirus replication after transplantation is associated with a decreased relapse risk: evidence for a putative virus-versus-leukemia effect in acute myeloid leukemia patients
- (2011) A. H. Elmaagacli et al. BLOOD
- Cytomegalovirus reactivation after allogeneic transplantation promotes a lasting increase in educated NKG2C+ natural killer cells with potent function
- (2011) B. Foley et al. BLOOD
- IPH2101, a novel anti-inhibitory KIR antibody, and lenalidomide combine to enhance the natural killer cell versus multiple myeloma effect
- (2011) D. M. Benson et al. BLOOD
- Biological effects and clinical significance of lenalidomide-induced tumour flare reaction in patients with chronic lymphocytic leukaemia: in vivo evidence of immune activation and antitumour response
- (2011) Asher A. Chanan-Khan et al. BRITISH JOURNAL OF HAEMATOLOGY
- IL-15:IL-15 receptor alpha superagonist complex: High-level co-expression in recombinant mammalian cells, purification and characterization
- (2011) Kai-ping Han et al. CYTOKINE
- Decreased NKp46 and NKG2D and elevated PD-1 are associated with altered NK-cell function in pediatric transplant patients with PTLD
- (2011) Silke Wiesmayr et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- Interleukin (IL)-2 and IL-15 have different effects on human natural killer lymphocytes
- (2011) Anne-Hélène Pillet et al. HUMAN IMMUNOLOGY
- Selenite Induces Posttranscriptional Blockade of HLA-E Expression and Sensitizes Tumor Cells to CD94/NKG2A-Positive NK Cells
- (2011) M. Enqvist et al. JOURNAL OF IMMUNOLOGY
- Activating Signals Dominate Inhibitory Signals in CD137L/IL-15 Activated Natural Killer Cells
- (2011) Hua Zhang et al. JOURNAL OF IMMUNOTHERAPY
- Expansion of a unique CD57+NKG2Chi natural killer cell subset during acute human cytomegalovirus infection
- (2011) S. Lopez-Verges et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Interleukin-15 biology and its therapeutic implications in cancer
- (2011) Jason C. Steel et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- Immunomodulatory effects of lenalidomide and pomalidomide on interaction of tumor and bone marrow accessory cells in multiple myeloma
- (2010) G. Gorgun et al. BLOOD
- The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody
- (2010) D. M. Benson et al. BLOOD
- A phase II study of allogeneic natural killer cell therapy to treat patients with recurrent ovarian and breast cancer
- (2010) Melissa A. Geller et al. CYTOTHERAPY
- Correlation of FCGR3A and EGFR germline polymorphisms with the efficacy of cetuximab in KRAS wild-type metastatic colorectal cancer
- (2010) Jan Pander et al. EUROPEAN JOURNAL OF CANCER
- Safety, Pharmacokinetics, and Immunomodulatory Effects of Lenalidomide in Children and Adolescents With Relapsed/Refractory Solid Tumors or Myelodysplastic Syndrome: A Children's Oncology Group Phase I Consortium Report
- (2010) Stacey L. Berg et al. JOURNAL OF CLINICAL ONCOLOGY
- IL-15R -IgG1-Fc Enhances IL-2 and IL-15 Anti-tumor Action through NK and CD8+ T Cells Proliferation and Activation
- (2010) Z. Wu et al. Journal of Molecular Cell Biology
- Safety and immunologic effects of IL-15 administration in nonhuman primates
- (2009) C. Berger et al. BLOOD
- Preclinical characterization of 1-7F9, a novel human anti-KIR receptor therapeutic antibody that augments natural killer-mediated killing of tumor cells
- (2009) F. Romagne et al. BLOOD
- Bortezomib treatment and regulatory T-cell depletion enhance the antitumor effects of adoptively infused NK cells
- (2009) A. Lundqvist et al. BLOOD
- Replicative potential of human natural killer cells
- (2009) Hiroyuki Fujisaki et al. BRITISH JOURNAL OF HAEMATOLOGY
- Expression of chimeric antigen receptors in natural killer cells with a regulatory-compliant non-viral method
- (2009) L Li et al. CANCER GENE THERAPY
- Clinical-grade ex vivo-expanded human natural killer cells up-regulate activating receptors and death receptor ligands and have enhanced cytolytic activity against tumor cells
- (2009) Maria Berg et al. CYTOTHERAPY
- In vivotumor cell rejection induced by NK cell inhibitory receptor blockade: Maintained tolerance to normal cells even in the presence of IL-2
- (2009) Gustaf Vahlne et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- Interleukin-12 Receptor β2: From Cytokine Receptor to Gatekeeper Gene in Human B-Cell Malignancies
- (2009) Vito Pistoia et al. JOURNAL OF CLINICAL ONCOLOGY
- A Programmed Switch from IL-15- to IL-2-Dependent Activation in Human NK Cells
- (2009) Anne-Hélène Pillet et al. JOURNAL OF IMMUNOLOGY
- Differential Effects of Selenium on Benign and Malignant Prostate Epithelial Cells: Stimulation of LNCaP Cell Growth by Noncytotoxic, Low Selenite Concentrations
- (2009) Nur Özten Kandaş et al. NUTRITION AND CANCER-AN INTERNATIONAL JOURNAL
- Genetic and antibody-mediated reprogramming of natural killer cell missing-self recognition in vivo
- (2009) C. Sola et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- PD-1 and Its Ligands in Tolerance and Immunity
- (2008) Mary E. Keir et al. Annual Review of Immunology
- Infusion of haplo-identical killer immunoglobulin-like receptor ligand mismatched NK cells for relapsed myeloma in the setting of autologous stem cell transplantation
- (2008) Jumei Shi et al. BRITISH JOURNAL OF HAEMATOLOGY
- Immunomodulatory drugs Revlimid® (lenalidomide) and CC-4047 induce apoptosis of both hematological and solid tumor cells through NK cell activation
- (2008) Dan Zhu et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Selective Induction of Expression of a Ligand for the NKG2D Receptor by Proteasome Inhibitors
- (2008) M. Vales-Gomez et al. CANCER RESEARCH
- Line of attack: NK cell specificity and integration of signals
- (2008) Yenan T Bryceson et al. CURRENT OPINION IN IMMUNOLOGY
- Multilineage hematopoietic recovery with concomitant antitumor effects using low dose Interleukin-12 in myelosuppressed tumor-bearing mice
- (2008) Lena A Basile et al. Journal of Translational Medicine
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started